Alumis (ALMS) stock soared after reporting successful Phase 3 results for envudeucitinib, a psoriasis treatment. Shares hit $22.30 before pulling back. The drug met all primary and secondary endpoints, potentially challenging current market leaders. With rapid efficacy and diversified pipeline, ALMS could see significant growth in the booming psoriasis market.

Despite some sentiment-driven volatility, ALMS remains a strong long-term play. The global psoriasis market offers immense potential, and the company’s immunology pipeline adds diversification. Analysts predict a 15% rally in the next four months, with a consensus “Strong Buy” rating and a target price of nearly $20. ALMS’s recent capital raises bode well for future commercialization efforts.

Read more at Yahoo Finance: Should You Chase the Rally in Alumis Stock Today?